{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:56:12Z","timestamp":1785488172557,"version":"3.56.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","journals.elsevierhealth.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.eururo.2016.04.033","type":"journal-article","created":{"date-parts":[[2016,5,6]],"date-time":"2016-05-06T14:57:48Z","timestamp":1462546668000},"page":"799-805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["A Narrative Review of Patient-reported Outcomes in Overactive Bladder: What is the Way of the Future?"],"prefix":"10.1016","volume":"70","author":[{"given":"Christopher R.","family":"Chapple","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Con J.","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Mako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2016.04.033_bib0250","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/nau.20798","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"29","author":"Haylen","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2016.04.033_bib0255","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1464-410X.2007.06517.x","article-title":"Redefining response in overactive bladder syndrome","volume":"99","author":"Payne","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2016.04.033_bib0260","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/nau.22210","article-title":"What are the best outcome measures when assessing treatment for LUTD?\u2014Achieving the most out of outcome evaluation: ICI-RS 2011","volume":"31","author":"Cotterill","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2016.04.033_bib0265","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1185\/03007995.2013.860021","article-title":"Defining response and non-response to treatment in patients with overactive bladder: a systematic review","volume":"30","author":"Goldman","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.eururo.2016.04.033_bib0270","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.urology.2008.05.033","article-title":"Validation of Treatment Benefit Scale for assessing subjective outcomes in treatment of overactive bladder","volume":"72","author":"Colman","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2016.04.033_bib0275","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00192-007-0351-7","article-title":"Detrusor overactivity does not predict outcome of sacral neuromodulation test simulation","volume":"18","author":"South","year":"2007","journal-title":"Int Urogynecol J"},{"issue":"Suppl1","key":"10.1016\/j.eururo.2016.04.033_bib0280","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3111\/13696998.2012.732635","article-title":"Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder","volume":"15","author":"Armstrong","year":"2012","journal-title":"J Med Econ"},{"key":"10.1016\/j.eururo.2016.04.033_bib0285","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.eururo.2012.08.047","article-title":"EAU guidelines on assessment and nonsurgical management of urinary incontinence","volume":"62","author":"Lucas","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.04.033_bib0290","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2165\/00019053-200725020-00005","article-title":"Disease burden of overactive bladder: quality-of-life data using ICI-recommended instruments","volume":"25","author":"Basra","year":"2007","journal-title":"Pharmacoeconomics"},{"issue":"Suppl2A","key":"10.1016\/j.eururo.2016.04.033_bib0295","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.urology.2006.05.042","article-title":"Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts","volume":"68","author":"Coyne","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2016.04.033_bib0300","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.urology.2006.02.042","article-title":"Symptom assessment tool for overactive bladder syndrome\u2014overactive bladder symptom score","volume":"68","author":"Homma","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2016.04.033_bib0305","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1023\/A:1016370925601","article-title":"Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q","volume":"11","author":"Coyne","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1016\/j.eururo.2016.04.033_bib0310","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1471-0528.1997.tb11006.x","article-title":"A new questionnaire to assess the quality of life of urinary incontinent women","volume":"104","author":"Kelleher","year":"1997","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.eururo.2016.04.033_bib0315","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.eururo.2006.01.007","article-title":"The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder","volume":"49","author":"Coyne","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.04.033_bib0320","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijgo.2013.07.013","article-title":"Patient-reported outcome of solifenacin treatment among women experiencing urinary urgency and urgency incontinence","volume":"124","author":"But","year":"2014","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.eururo.2016.04.033_bib0325","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.clinthera.2006.11.010","article-title":"Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT)","volume":"28","author":"Garely","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.eururo.2016.04.033_bib0330","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/ijcp.12087","article-title":"Validation study of the Self-Assessment Goal Achievement (SAGA) questionnaire for lower urinary tract symptoms","volume":"67","author":"Brubaker","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.eururo.2016.04.033_bib0335","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2288-9-55","article-title":"A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder","volume":"9","author":"Lee","year":"2009","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.eururo.2016.04.033_bib0340","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrurol.2011.99","article-title":"The placebo effect in overactive bladder syndrome","volume":"8","author":"Mangera","year":"2011","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2016.04.033_bib0345","first-page":"4","article-title":"Current perspectives on management of urgency using bladder and behavioural training","volume":"16","author":"Burgio","year":"2004","journal-title":"J Am Acad Nurse Pract"},{"issue":"Suppl6","key":"10.1016\/j.eururo.2016.04.033_bib0350","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.juro.2012.09.079","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFA guideline","volume":"188","author":"Gormley","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.04.033_bib0355","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.urology.2010.06.044","article-title":"Assessment of overactive bladder symptoms: comparison of 3-day bladder diary and the overactive bladder symptoms score","volume":"77","author":"Homma","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2016.04.033_bib0360","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s00192-011-1486-0","article-title":"The psychometric validation of a 1-week recall period for the OAB-q","volume":"22","author":"Coyne","year":"2011","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.eururo.2016.04.033_bib0365","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF02850085","article-title":"Validation of an Overactive Bladder Awareness Tool for use in primary care settings","volume":"22","author":"Coyne","year":"2005","journal-title":"Adv Ther"},{"key":"10.1016\/j.eururo.2016.04.033_bib0370","article-title":"Development and testing of a new instrument to measure fluid intake, output, and urinary symptoms: the questionnaire-based voiding diary","volume":"193","author":"Arya","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.eururo.2016.04.033_bib0375","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/nau.21091","article-title":"Construct validity of a questionnaire to measure the type of fluid intake and type of urinary incontinence","volume":"30","author":"Arya","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2016.04.033_bib0380","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/nau.20027","article-title":"Voiding diary for the evaluation of urinary incontinence and lower urinary tract symptoms: prospective assessment of patient compliance and burden","volume":"23","author":"Ku","year":"2004","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2016.04.033_bib0385","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00192-014-2470-2","article-title":"Voiding diaries: adherence in the clinical setting","volume":"26","author":"Pauls","year":"2015","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.eururo.2016.04.033_bib0390","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.juro.2009.01.042","article-title":"Women overestimate daytime urinary frequency: the importance of the bladder diary","volume":"181","author":"Stav","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.04.033_bib0395","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ajog.2004.03.089","article-title":"The effect of previous treatment experience and incontinence severity on the placebo response of stress urinary incontinence","volume":"191","author":"Yalcin","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.eururo.2016.04.033_bib0400","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/00006199-198509000-00005","article-title":"Urinary incontinence verification in elderly men","volume":"34","author":"Robb","year":"1985","journal-title":"Nurs Res"},{"key":"10.1016\/j.eururo.2016.04.033_bib0405","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/nau.20994","article-title":"Urinary diaries: evidence for the development and validation of diary content, format and duration","volume":"30","author":"Bright","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2016.04.033_bib0410","doi-asserted-by":"crossref","first-page":"e2365","DOI":"10.1136\/bmj.e2365","article-title":"The management of overactive bladder syndrome","volume":"344","author":"Marinkovic","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2016.04.033_bib0415","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1185\/03007990902774765","article-title":"Optimal recall periods for patient-reported outcomes: challenges and potential solutions","volume":"25","author":"Stull","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.eururo.2016.04.033_bib0420","first-page":"812","article-title":"The urinary diary in evaluation of incontinent women: a test-retest analysis","volume":"71","author":"Wyman","year":"1988","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.eururo.2016.04.033_bib0425","series-title":"Urogynecology: The Kings Approach","author":"Barnick","year":"1977"},{"key":"10.1016\/j.eururo.2016.04.033_bib0430","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pain.2008.03.024","article-title":"The accuracy of pain and fatigue items across different reporting periods","volume":"139","author":"Broderick","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.eururo.2016.04.033_bib0435","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jpainsymman.2009.12.010","article-title":"Does recall period have an effect on cancer patients\u2019 rating of the severity of multiple symptoms?","volume":"40","author":"Shi","year":"2010","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.eururo.2016.04.033_bib0440","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jpainsymman.2008.02.009","article-title":"Assessing persistent cancer pain: a comparison of current pain ratings and pain recalled from the past week","volume":"37","author":"Shi","year":"2009","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.eururo.2016.04.033_bib0445","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.juro.2013.06.038","article-title":"A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis\/bladder pain syndrome","volume":"191","author":"Bosch","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.04.033_bib0450","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.juro.2014.09.091","article-title":"A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with Mirabegron for overactive bladder induced by benign prostatic obstruction","volume":"193","author":"Ichihara","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.04.033_bib0455","first-page":"1707","article-title":"Solifenacin\/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia","volume":"9","author":"Dimitropoulos","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.eururo.2016.04.033_bib0460","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1303646","article-title":"Comparison of pregabalin with pramipexole for restless legs syndrome","volume":"370","author":"Allen","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2016.04.033_bib0465","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.sleep.2014.09.015","article-title":"Pramipexole for Chinese people with primary restless legs syndrome: a 12-week multicenter, randomized, double-blind study","volume":"16","author":"Zhang","year":"2015","journal-title":"Sleep Med"},{"key":"10.1016\/j.eururo.2016.04.033_bib0470","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/ene.12286","article-title":"Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndrome patients with low serum ferritin","volume":"21","author":"Lee","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.eururo.2016.04.033_bib0475","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0304-3959(00)00305-5","article-title":"Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers","volume":"88","author":"Stewart","year":"2000","journal-title":"Pain"},{"key":"10.1016\/j.eururo.2016.04.033_bib0480","series-title":"Reflection Paper on the Regulatory Guidance for the Use of Health-Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products","year":"2005"},{"key":"10.1016\/j.eururo.2016.04.033_bib0485","series-title":"Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims","year":"2009"},{"key":"10.1016\/j.eururo.2016.04.033_bib0490","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","article-title":"Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: Part 1\u2014eliciting concepts for a new PRO instrument","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816301439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816301439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T14:02:55Z","timestamp":1600524175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283816301439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0302283816301439"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2016.04.033","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Narrative Review of Patient-reported Outcomes in Overactive Bladder: What is the Way of the Future?","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2016.04.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}